In This Section      
 

Ciccarone Articles

Ciccarone Center Research

Topic

ASCVD (Atherosclerotic Cardiovascular Disease)

Landmark Articles

Nonfatal outcomes in the primary prevention of atherosclerotic cardiovascular disease: is all-cause mortality really all that matters?
By: Czarny MJ, Martin SS, Kohli P, Metkus T, Blumenthal RS.
This article clearly shows that major nonfatal cardiovascular outcomes are very important to take into account when designing primary prevention guidelines.
Read on Pubmed
Epicardial fat is associated with duration of antiretroviral therapy and coronary atherosclerosis.
By: Brener M, Ketlogetswe K, Budoff M, Jacobson LP, Li X, Rezaeian P, Razipour A, Palella FJ Jr, Kingsley L, Witt MD, George RT, Post WS.
Greater epicardial fat volume in HIV-infected men and its association with coronary plaque and antiretroviral therapy duration suggest potential mechanisms that might lead to increased risk for cardiovascular disease in HIV.
Read on Pubmed
Baseline subclinical atherosclerosis burden and distribution are associated with frequency and mode of future coronary revascularization: multi-ethnic study of atherosclerosis.
By: Silverman MG, Harkness JR, Blankstein R, Budoff MJ, Agatston AS, Carr JJ, Lima JA, Blumenthal RS, Nasir K, Blaha MJ.
There was a strong association between the baseline burden and regional distribution of CAC and the risk and type of future coronary revascularization among asymptomatic subjects.
Read on Pubmed
2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults.
By: Abd TT, Misra S, Ojeifo O, Martin SS, Blumenthal RS, Foody J, Wong ND.
Read on Pubmed
Fatty acids and TxA2 generation, in the absence of platelet-COX-1 activity.
By: DeFilippis AP, Rai SN, Cambon A, Miles R, Saenger AK, Blumenthal RS, Jaffe AS, Moser AB, Jones RO, Bolli R, Schulman SP.
This study shows that baseline omega-3 fatty acid levels do not influence TxA(2) generation in patients with or at high risk for CVD receiving adequate aspirin therapy.
Read on Pubmed
2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk.
By: Abd TT, Misra S, Ojeifo O, Martin SS, Blumenthal RS, Foody J, Wong ND.
The 2013 lifestyle guidelines provide guidance in three narrowly focused areas: 1) the effect of dietary patterns and macronutrient composition on CVD risk factors; 2) the effect of sodium and potassium on CVD risk factors; and 3) the effect of physical activity on blood pressure and lipids.
Read on Pubmed
Associations between HIV infection and subclinical coronary atherosclerosis.
By: Post WS, Budoff M, Kingsley L, Palella FJ Jr, Witt MD, Li X, George RT, Brown TT, Jacobson LP.
Coronary artery plaque, especially noncalcified plaque, is more prevalent and extensive in HIV-infected men, independent of CAD risk factors.
Read on Pubmed
Focused update on the 2013-2014 cardiovascular disease prevention guidelines.
By: Abd TT, Misra S, Ojeifo O, Martin SS, Blumenthal RS, Foody J, Wong ND.
Current guidelines for high-density lipoprotein cholesterol in therapy and future directions.
By: Subedi BH, Joshi PH, Jones SR, Martin SS, Blaha MJ, Michos ED.
This review outlined current therapies and described future directions for potential new approaches for HDL therapeutics, including HDL infusions, delipidated HDL, liver X receptor agonists, Apo A-I upregulators, Apo A mimetics, and gene therapy.
Read on Pubmed
Concepts and controversies: the 2013 American College of Cardiology/American Heart Association risk assessment and cholesterol treatment guidelines.
By: Martin SS, Blumenthal RS.
This editorial discusses the strengths and limitations of the new prevention guidelines.
Read on Pubmed